PD-L1 Antikörper (Extracellular Domain)

Produktnummer ABIN1449244

Dieses Maus Monoklonal-Antikörper erkennt spezifisch PD-L1 in FACS und IHC (p). Er zeigt eine Reaktivität gegenüber Human und wurde in 6+ Publikationen erwähnt.

Kurzübersicht für PD-L1 Antikörper (Extracellular Domain) (ABIN1449244)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: 27A2

Produktdetails anti-PD-L1 Antikörper

Bindungsspezifität: Extracellular Domain

Spezifität: This antibody reacts with human CD274 antigen.

Aufreinigung: Protein A agarose

Immunogen: Recombinant human PD-L1 extracellular domain

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: PBS containing 50 % glycerol, pH 7.2. No preservative is contained.

Konservierungsmittel: Without preservative

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Upon receipt, store (in aliqouts) at -20 °C.

Referenzen für anti-PD-L1 Antikörper (ABIN1449244)

Gadiot, Hooijkaas, Kaiser, van Tinteren, van Boven, Blank: "Overall survival and PD-L1 expression in metastasized malignant melanoma." in: Cancer, Vol. 117, Issue 10, pp. 2192-201, (2011) (PubMed).

Hino, Kabashima, Kato, Yagi, Nakamura, Honjo, Okazaki, Tokura: "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma." in: Cancer, Vol. 116, Issue 7, pp. 1757-66, (2010) (PubMed).

Schuchmann, Meyer, Distler, von Stebut, Kuball, Schnürer, Wölfel, Theobald, Konur, Gregor, Schreiner, Huber, Galle, Otto, Herr: "The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation." in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Vol. 8, Issue 11, pp. 2434-44, (2008) (PubMed).

Fancke, Suter, Hochrein, OKeeffe: "M-CSF: a novel plasmacytoid and conventional dendritic cell poietin." in: Blood, Vol. 111, Issue 1, pp. 150-9, (2008) (PubMed).

Hamanishi, Mandai, Iwasaki, Okazaki, Tanaka, Yamaguchi, Higuchi, Yagi, Takakura, Minato, Honjo, Fujii: "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 9, pp. 3360-5, (2007) (PubMed).

Vega, Jazirehi, Huerta-Yepez, Bonavida et al.: "Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and ..." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 4, pp. 2174-83, (2005) (PubMed).

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: CD274 / PDL1

Hintergrund: Programmed death ligand 1 (PD-L1, also known as CD274/B7-H1), a member of B7 family was identified by searching for mo lecules that share homology with the immunogloblin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database. PD-L1 is a ligand for programmed death 1 (PD-1) which belongs to the CD28/CTLA4 subfamily. Although in vitro study indicated that the cross-linking of PD-1 by PD-L1 leads to down-regulation of T-cell responses, some studies have shown that T cells stimulated with low levels of anti-CD3 and immobilized PD-L1-Ig were activated, proliferation and production of IFN- γ GM-CSF and IL-10 from the T cells were enhanced. The role of PD-L1 is now debatable.Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Gen-ID: 29126

NCBI Accession: NP_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints